This study indicated the following two findings in patients with unresectable advanced or recurrent G/GEJ cancer who treated chemotherapy and/or anti-PD-1 therapy (immunotherapy): (1) The Anti-PD-1+TR group had significantly longer survival compared to the Anti-PD-1 group; and (2) in comparison to tumor cells after chemotherapy, tumor cells after anti-PD-1 therapy showed significantly downregulated expression of HLA class I, which may be associated with the activation of TGF-β pathway. Here, TGFB1 is linked to neoplasm.